Daewoong Pharmaceutical Unveils Violet Clinical Cases in China for the First Time

Global Scientific Session Held at AMWC CHINA 2025 in Chengdu

Daewoong Pharmaceutical is accelerating its global expansion by introducing its fat-dissolving injection, Violet, for the first time at China's largest aesthetic and plastic surgery conference.

At AMWC CHINA 2025 held in Chengdu, China on the 17th of last month, clinical results and procedure cases of Violet are being presented. Daewoong Pharmaceutical

On the 18th, Daewoong Pharmaceutical announced that it held the "Violet Scientific Forum" at AMWC CHINA 2025 in Chengdu, China, on the 17th of last month. During the forum, the company presented clinical data, differentiating features, and procedure cases of the fat-dissolving injection Violet to Chinese and global medical professionals. AMWC CHINA 2025 is the largest aesthetic and plastic surgery conference in China.

Violet is a fat-dissolving injection containing deoxycholic acid (DCA) that Daewoong Pharmaceutical launched in Korea in 2021. It is the only product in Korea to have its safety and efficacy verified through a large-scale Phase 3 clinical trial involving more than 960 participants, as well as post-marketing surveillance (PMS).

This year’s AMWC CHINA 2025 attracted more than 200 global speakers, including local Chinese medical professionals, and over 200 companies. Daewoong Pharmaceutical aims to use the forum and its booth operations as a strategic foothold to expand Violet into the global market.

At the event, Professor Wang Hang, a board member of AMWC CHINA and a plastic surgeon at Sichuan University, served as chair and introduced trends in the Chinese fat-dissolving market along with the unique advantages of Violet. Following this, Ko Beomjun, Director of Doctors Dermatology Clinic Sinsa Branch, presented the results of Violet’s Phase 3 clinical trials in Korea and patient case studies, emphasizing Violet’s efficacy and safety based on years of accumulated Korean clinical data. Li Xue, Director of ARSMO Hainan, also participated as a speaker, drawing significant interest from local medical professionals.

Yoon Junsu, Head of Nabota Business Division at Daewoong Pharmaceutical, stated, "This AMWC CHINA 2025 was not only Violet’s first stage in advancing from Korea to the global market, but also a meaningful occasion where medical professionals from Korea and abroad jointly confirmed its potential. Moving forward, Violet will grow into a blockbuster brand leading Daewoong Pharmaceutical’s global medical aesthetics portfolio alongside Nabota."

This content was produced with the assistance of AI translation services.